Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens

被引:41
|
作者
Kiyotani, Kazuma [1 ]
Chan, Hiu Ting [1 ]
Nakamura, Yusuke [2 ,3 ]
机构
[1] Japanese Fdn Canc Res, Project Immunogen, Canc Precis Med Ctr, Tokyo, Japan
[2] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA
来源
CANCER SCIENCE | 2018年 / 109卷 / 03期
关键词
cancer precision medicine; immune checkpoint inhibitor; neoantigen; next-generation sequencing; T-cell receptor repertoire; GENERATION SEQUENCING DATA; T-CELL EPITOPES; METASTATIC MELANOMA; MASS-SPECTROMETRY; PD-1; BLOCKADE; NEO-ANTIGENS; PROTEASOMAL CLEAVAGE; SOMATIC MUTATIONS; COMPLETE RESPONSE; CTLA-4;
D O I
10.1111/cas.13498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Utilizing the host immune system to eradicate cancer cells has been the most investigated subject in the cancer research field in recent years. However, most of the studies have focused on highly variable responses from immunotherapies such as immune checkpoint inhibitors, from which the majority of patients experienced no or minimum clinical benefit. Advances in genomic sequencing technologies have improved our understanding of immunopharmacogenomics and allowed us to identify novel cancer-specific immune targets. Highly tumor-specific antigens, neoantigens, are generated by somatic mutations that are not present in normal cells. It is plausible that by targeting antigens with high tumor-specificity, such as neoantigens, the likelihood of toxic effects is very limited. However, understanding the interaction between neoantigens and the host immune system remains a significant challenge. This review focuses on the potential use of neoantigen-targeted immunotherapies in cancer treatment and the recent progress of different strategies in predicting, identifying, and validating neoantigens. Successful identification of highly tumor-specific antigens accelerates the development of personalized immunotherapy with no or minimum adverse effects and with a broader coverage of patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [31] Cancer neoantigens as potential targets for immunotherapy
    Ma, Weijie
    Pham, Brian
    Li, Tianhong
    CLINICAL & EXPERIMENTAL METASTASIS, 2022, 39 (01) : 51 - 60
  • [32] Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Lu, Ligong
    Jiang, Jun
    Zhan, Meixiao
    Zhang, Hui
    Wang, Qian-Ting
    Sun, Sheng-Nan
    Guo, Xiao-Kai
    Yin, Hua
    Wei, Yadong
    Liu, Jun O.
    Li, Shi-You
    Li, Yong
    He, You-Wen
    HEPATOLOGY, 2021, 73 (01) : 414 - 421
  • [33] Novel tools to assist neoepitope targeting in personalized cancer immunotherapy
    Saini, S. K.
    Rekers, N.
    Hadrup, S. R.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 10
  • [34] Novel Methodology for the Design of Personalized Cancer Vaccine Targeting Neoantigens: Application to Pancreatic Ductal Adenocarcinoma
    Savsani, Kush
    Dakshanamurthy, Sivanesan
    DISEASES, 2024, 12 (07)
  • [35] Selection of targeted neoantigens for personalized cancer vaccines
    Keskin, Derin
    CANCER RESEARCH, 2024, 84 (07)
  • [36] Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy
    Nakajima, Hiromichi
    Nakatsura, Tetsuya
    IMMUNOLOGICAL MEDICINE, 2021, 44 (01) : 10 - 15
  • [37] Mutation-Derived Neoantigens for Cancer Immunotherapy
    Castle, John C.
    Uduman, Mohamed
    Pabla, Simarjot
    Stein, Robert B.
    Buell, Jennifer S.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [38] Inducing neoantigens in therapeutic and prophylactic cancer immunotherapy
    Hidalgo, Greta Garrido
    Levay, Agata
    Berezhnoy, Alexey
    Schrand, Brett
    Gilboa, Eli
    CANCER RESEARCH, 2017, 77
  • [39] The perfect personalized cancer therapy: cancer vaccines against neoantigens
    Aurisicchio, Luigi
    Pallocca, Matteo
    Ciliberto, Gennaro
    Palombo, Fabio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [40] Neoantigens in cancer immunotherapy: focusing on alternative splicing
    Huang, Peng
    Wen, Feng
    Tuerhong, Nuerye
    Yang, Yang
    Li, Qiu
    FRONTIERS IN IMMUNOLOGY, 2024, 15